Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 2/20 | 0.41 |
| ▸ | F3 | P13726 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31213151 | 0.91 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18954218 | 0.91 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL25305244 | 0.85 | CNR1 (0.49) | ALDH1A1CNR1CNR2LPAR2LPAR3 | |
| SCHEMBL27320 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CNR1CNR2F7F3 | |
| SCHEMBL15930623 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CNR1CNR2F7F3 | |
| SCHEMBL16902073 | 0.78 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2F7F3 | |
| SCHEMBL15743534 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CNR1CNR2F7F3 | |
| SCHEMBL18669396 | 0.77 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL19742389 | 0.77 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15754779 | 0.77 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3329003-A2 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | Arbutus Biopharma Corporation (CA) | 2018-06-06 | — | — | EP | claimed |
| WO-2017019891-A2 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-02-02 | — | — | WO | claimed |
| WO-2016197133-A1 | DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-12-08 | — | — | WO | claimed |
| WO-2016154127-A2 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2016-09-29 | — | — | WO | claimed |
| EP-2506879-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | Protiva Biotherapeutics Inc. (CA) | 2012-10-10 | — | — | EP | claimed |
| EP-2480668-A2 | COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER | Protiva Biotherapeutics Inc. (CA) | 2012-08-01 | — | — | EP | claimed |
| WO-2011066651-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-06-09 | — | — | WO | claimed |
| WO-2011038160-A2 | COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | WO | claimed |
| EP-4347836-A2 | COMPOSITIONS AND METHODS FOR SILENCING CARBONIC ANHYDRASE 2 EXPRESSION | Alnylam Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4333898-A2 | PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023218420-A1 | MRNA COMPOSITIONS FOR INDUCING LATENT HIV-1 REVERSAL | Janssen Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4178613-A1 | RNA REPLICON VACCINES AGAINST HBV | Janssen Sciences Ireland Unlimited Company (IE) | 2023-05-17 | — | — | EP | disclosed |
| EP-4157344-A2 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | CureVac SE (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-3986452-A1 | ROTAVIRUS MRNA VACCINE | CureVac AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| WO-2017140905-A1 | ZIKA VIRUS VACCINE | CUREVAC AG (DE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2016079197-A1 | DELIVERY ENHANCERS FOR CONJUGATED SIRNA AND LIPID NANOPARTICLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-05-26 | — | — | WO | disclosed |
| WO-2014008334-A1 | STABLE NON-AGGREGATING NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| EP-2449106-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | Protiva Biotherapeutics Inc. (CA) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011141704-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011000108-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |